Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears…
Articles by Marisa Wexler, MS
Note: This story was updated May 28, 2026, to clarify the indications for which Cereno Scientific’s experimental therapies are being…
Using artificial intelligence (AI) analyses of clinical data from hundreds of patients, scientists have created a new system to calculate…
Using artificial intelligence (AI) and analyzing genetic data focused on two primary biochemical processes, a team of scientists in China…
A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary…
Scientists in China have developed a phosphodiesterase-5 (PDE5) inhibitor for pulmonary arterial hypertension (PAH) that reduced disease severity in…
Advocates worldwide are gearing up for World Pulmonary Hypertension Day on May 5, focusing this year on the critical…
Babies with bronchopulmonary dysplasia (BPD), a lung disorder that affects premature infants and can lead to pulmonary hypertension (PH),…
Children with pulmonary hypertension (PH) engage in fewer and shorter bouts of intense physical activity than their peers, according…
The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, Inhibikase Therapeutics’ experimental formulation…
Patients with interstitial lung diseases (ILDs) who require supplemental oxygen are more than three times as likely to experience…
Anumana‘s AI-enabled algorithm for the early detection of pulmonary hypertension (PH) has been cleared for use by the…